Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index

Science Translational Medicine

Volumn 5, Issue 207, 2013, Pages

  Desnoyers, Luc R ^a   Vasiljeva, Olga ^a   Richardson, Jennifer H ^a   Yang, Annie ^a   Menendez, Elizabeth E M ^a   Liang, Tony W ^a   Wong, Chihunt ^a   Bessette, Paul H ^a   Kamath, Kathy ^a   Moore, Stephen J ^a   Sagert, Jason G ^a   Hostetter, Daniel R ^a   Han, Fei ^a   Gee, Jason ^a   Flandez, Jeanne ^a   Markham, Kate ^a   Nguyen, Margaret ^a   Krimm, Michael ^a   Wong, Kenneth R ^a   Liu, Shouchun ^a   Daugherty, Patrick S ^b   West, James W ^a   Lowman, Henry B ^a   more..

^a CytomX Therapeutics Inc   (United States)

^b University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G; RECOMBINANT EPIDERMAL GROWTH FACTOR RECEPTOR DIRECTED PROBODY; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; MICE; MICE, NUDE; NEOPLASMS; PRODRUGS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886423341     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006682     Document Type: Article

References (30)

1. K. Strebhardt, A. Ullrich, Paul Ehrlich's magic bullet concept: 100 Years of progress. Nat. Rev. Cancer 8, 473-480 (2008).
2. J. M. Reichert, Marketed therapeutic antibodies compendium. MAbs 4, 413-415 (2012).
3. B. A. Teicher, Antibody-drug conjugate targets. Curr. Cancer Drug Targets 9, 982-1004 (2009).
4. C. A. Hudis, Trastuzumab - Mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51 (2007).
5. S. Verma, D. Miles, L. Gianni, I. E. Krop, M. Welslau, J. Baselga, M. Pegram, D. Y. Oh, V. Diéras, E. Guardino, L. Fang, M. W. Lu, S. Olsen, K. Blackwell; EMILIA Study Group, Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Eng. J. Med. 367, 1783-1791 (2012).
6. J. Baselga, C. L. Arteaga, Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 23, 2445-2459 (2005).
7. N. E. Hynes, H. A. Lane, ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 (2005).
8. N. E. Hynes, G. MacDonald, ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 21, 177-184 (2009).
9. H. Modjtahedi, S. Essapen, Epidermal growth factor receptor inhibitors in cancer treatment: Advances, challenges and opportunities. Anticancer Drugs 20, 851-855 (2009).
10. R. Peréz-Soler, L. Saltz, Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J. Clin. Oncol. 23, 5235-5246 (2005).
11. Erbitux (cetuximab) prescribing information, ImClone LLC, a wholly owned subsidiary of Eli Lilly and Company, and Bristol-Myers Squibb Company, 693US13PBS01901 (2013).
12. L. Regales, Y. Gong, R. Shen, E. de Stanchina, I. Vivanco, A. Goel, J. A. Koutcher, M. Spassova, O. Ouerfelli, I. K. Mellinghoff, M. F. Zakowski, K. A. Politi, W. Pao, Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 119, 3000-3010 (2009).
13. Y. Y. Janjigian, C. G. Azzoli, L.M. Krug, L. K. Pereira, N. A. Rizvi, M. C. Pietanza, M. G. Kris, M. S. Ginsberg, W. Pao, V. A. Miller, G. J. Riely, Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin. Cancer Res. 17, 2521-2527 (2011).
14. A. Cavazzoni, R. R. Alfieri, D. Cretella, F. Saccani, L. Ampollini, M. Galetti, F. Quaini, G. Graiani, D. Madeddu, P. Mozzoni, E. Galvani, S. La Monica, M. Bonelli, C. Fumarola, A. Mutti, P. Carbognani, M. Tiseo, E. Barocelli, P. G. Petronini, A. Ardizzoni, Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines. Mol. Cancer 11, 91 (2012).
15. D. Patel, A. Lahiji, S. Patel, M. Franklin, X. Jimenez, D. J. Hicklin, X. Kang, Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res. 27, 3355-3366 (2007).
16. H. Riechelmann, A. Sauter, W. Golze, G. Hanft, C. Schroen, K. Hoermann, T. Erhardt, S. Gronau, Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 44, 823-829 (2008).
17. T. T. Hansel, H. Kropshofer, T. Singer, J. A. Mitchell, A. J. George, The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9, 325-338 (2010).
18. K. Even-Desrumeaux, D. Baty, P. Chames, State of the art in tumor antigen and biomarker discovery. Cancers 3, 2554-2596 (2011).
19. O. Erster, J. M. Thomas, J. Hamzah, A. M. Jabaiah, J. A. Getz, T. D. Schoep, S. S. Hall, E. Ruoslahti, P. S. Daugherty, Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J. Control. Release 161, 804-812 (2012).
20. J. J. Rice, A. Schohn, P. H. Bessette, K. T. Boulware, P. S. Daugherty, Bacterial display using circularly permuted outer membrane protein OmpX yields high affinity peptide ligands. Protein Sci. 15, 825-836 (2006).
21. L. C. van Kempen, K. E. de Visser, L. M. Coussens, Inflammation, proteases and cancer. Eur. J. Cancer 42, 728-734 (2006).
22. K. T. Boulware, P. S. Daugherty, Protease specificity determination by using cellular libraries of peptide substrates (CLiPS). Proc. Natl. Acad. Sci. U.S.A. 103, 7583-7588 (2006).
23. S. Ulisse, E. Baldini, S. Sorrenti, M. D'Armiento, The urokinase plasminogen activator system: A target for anti-cancer therapy. Curr. Cancer Drug Targets 9, 32-71 (2009).
24. K. Uhland, Matriptase and its putative role in cancer. Cell. Mol. Life Sci. 63, 2968-2978 (2006).
25. A. M. LeBeau, M. Lee, S. T. Murphy, B. C. Hann, R. S. Warren, R. D. Santos, J. Kurhanewicz, S. M. Hanash, H. F. VanBrocklin, C. S. Craik, Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc. Natl. Acad. Sci. U.S.A. 110, 93-98 (2013).
26. C. Liu, C. Sun, H. Huang, K. Janda, T. Edgington, Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63, 2957-2964 (2003).
27. X. Jin, T. Hirosaki, C. Y. Lin, R. B. Dickson, S. Higashi, H. Kitamura, K. Miyazaki, Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin. J. Cell. Biochem. 95, 632-647 (2005).
28. G. Liu, M. A. Shuman, R. L. Cohen, Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer 60, 501-506 (1995).
29. D. Raben, B. Helfrich, D. C. Chan, F. Ciardiello, L. Zhao, W. Franklin, A. E. Barón, C. Zeng, T. K. Johnson, P. A. Bunn Jr., The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer Res. 11, 795-805 (2005).
30. E. Van Cutsem, S. Tejpar, D. Vanbeckevoort, M. Peeters, Y. Humblet, H. Gelderblom, J. B. Vermorken, F. Viret, B. Glimelius, E. Gallerani, A. Hendlisz, A. Cats, M. Moehler, X. Sagaert, S. Vlassak, M. Schlichting, F. Ciardiello, Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: The randomized EVEREST study. J. Clin. Oncol. 10, 2861-2868 (2012).